Personalization is the new king of global outsourcing. Patients are crying out for more flexible, more diverse and less burdensome trial designs, while the ever larger CROs become less versatile with every merger. It’s no surprise that pharma is beginning to ask questions about how to receive the one-to-one attention we need to build innovative global trials.

During this webinar, Mallinckrodt Pharmaceuticals, Amsterdam UMC, Comac Medical, Peachtree and Julius Clinical explored the emerging future of outsourcing regional and global trials.

This exclusive discussion covered:

  • Overcoming concerns around perceived risks and inefficiencies when building tailor-made trial solutions
  • How to build an outsourcing strategy that will deliver greater design flexibility and closer working with industry expert KOL’s
  • Where to find the right partners who can deliver personalized access to local sites, patient populations and scientific support
  • Why developing a peer-to-peer approach with local experts results in patient-preferred trial designs, outcomes and deliverables

Panel speakers:

  • Anne Marie Inglis, PhD, Senior Director, Clinical Operations, Mallinckrodt Pharmaceuticals
  • Dr. Philip Scheltens, Professor of Cognitive Neurology and Director of the Alzheimer Center, Amsterdam UMC
  • Tsvetelina Ivanova, Chief Compliance Manager, Comac Medical
  • Keith Coffee, SVP Medical and Scientific Affairs, Peachtree
  • Hans van Dijk, Chief Operating Officer, Julius Clinical

Watch webinar

"*" indicates required fields

*
*
This field is for validation purposes and should be left unchanged.